Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

TTRX vs PRAX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
TTRX
Turn Therapeutics Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$112M
5Y Perf.-11.5%
PRAX
Praxis Precision Medicines, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$9.63B
5Y Perf.-4.6%

TTRX vs PRAX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
TTRX logoTTRX
PRAX logoPRAX
IndustryBiotechnologyBiotechnology
Market Cap$112M$9.63B
Revenue (TTM)$-92K
Net Income (TTM)$-2M$-327M
Total Debt$121K$110K
Cash & Equiv.$873K$357M

Quick Verdict: TTRX vs PRAX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PRAX leads in 3 of 5 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Turn Therapeutics Inc. is the stronger pick specifically for capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
TTRX
Turn Therapeutics Inc.
The Income Pick

TTRX is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 1.45
  • Lower volatility, beta 1.45, current ratio 1.55x
  • Beta 1.45, current ratio 1.55x
Best for: income & stability and sleep-well-at-night
PRAX
Praxis Precision Medicines, Inc.
The Long-Run Compounder

PRAX carries the broadest edge in this set and is the clearest fit for long-term compounding.

  • -20.1% 10Y total return vs TTRX's -45.8%
  • 2.4% margin vs TTRX's 1.4%
  • +7.7% vs TTRX's -45.8%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
Quality / MarginsPRAX logoPRAX2.4% margin vs TTRX's 1.4%
Stability / SafetyTTRX logoTTRXBeta 1.45 vs PRAX's 1.55
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)PRAX logoPRAX+7.7% vs TTRX's -45.8%
Efficiency (ROA)PRAX logoPRAX-40.2% ROA vs TTRX's -87.1%

TTRX vs PRAX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

TTRXTurn Therapeutics Inc.

Segment breakdown not available.

PRAXPraxis Precision Medicines, Inc.
FY 2024
License
76.8%$9M
Upfront Payment
23.2%$3M

TTRX vs PRAX — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPRAXLAGGINGTTRX

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.
MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
RevenueTrailing 12 months-$92,000
EBITDAEarnings before interest/tax-$357M
Net IncomeAfter-tax profit-$327M
Free Cash FlowCash after capex-$283M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+2.7%
Insufficient data to determine a leader in this category.

Valuation Metrics

Insufficient data to determine a leader in this category.
MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
Market CapShares × price$112M$9.6B
Enterprise ValueMkt cap + debt − cash$111M$9.3B
Trailing P/EPrice ÷ TTM EPS-24.72x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share8.54x
Price / FCFMarket cap ÷ FCF
Insufficient data to determine a leader in this category.

Profitability & Efficiency

PRAX leads this category, winning 4 of 4 comparable metrics.
MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
ROE (TTM)Return on equity-43.0%
ROA (TTM)Return on assets-87.1%-40.2%
ROICReturn on invested capital-65.0%
ROCEReturn on capital employed-125.5%-49.3%
Piotroski ScoreFundamental quality 0–933
Debt / EquityFinancial leverage0.00x
Net DebtTotal debt minus cash-$751,563-$357M
Cash & Equiv.Liquid assets$872,599$357M
Total DebtShort + long-term debt$121,036$110,000
Interest CoverageEBIT ÷ Interest expense
PRAX leads this category, winning 4 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

PRAX leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in PRAX five years ago would be worth $7,918 today (with dividends reinvested), compared to $5,421 for TTRX. Over the past 12 months, PRAX leads with a +775.0% total return vs TTRX's -45.8%. The 3-year compound annual growth rate (CAGR) favors PRAX at 174.9% vs TTRX's -18.5% — a key indicator of consistent wealth creation.

MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
YTD ReturnYear-to-date-19.1%+16.4%
1-Year ReturnPast 12 months-45.8%+775.0%
3-Year ReturnCumulative with dividends-45.8%+1976.5%
5-Year ReturnCumulative with dividends-45.8%-20.8%
10-Year ReturnCumulative with dividends-45.8%-20.1%
CAGR (3Y)Annualised 3-year return-18.5%+174.9%
PRAX leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

PRAX leads this category, winning 2 of 2 comparable metrics.

TTRX is the less volatile stock with a 1.45 beta — it tends to amplify market swings less than PRAX's 1.55 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PRAX currently trades 93.6% from its 52-week high vs TTRX's 14.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
Beta (5Y)Sensitivity to S&P 5001.45x1.40x
52-Week HighHighest price in past year$26.50$356.00
52-Week LowLowest price in past year$2.57$35.18
% of 52W HighCurrent price vs 52-week peak+14.3%+93.6%
RSI (14)Momentum oscillator 0–10061.155.6
Avg Volume (50D)Average daily shares traded23K378K
PRAX leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates TTRX as "Buy" and PRAX as "Buy".

MetricTTRX logoTTRXTurn Therapeutics…PRAX logoPRAXPraxis Precision …
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$548.80
# AnalystsCovering analysts116
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

PRAX leads in 3 of 6 categories — strongest in Profitability & Efficiency and Total Returns.

Best OverallPraxis Precision Medicines,… (PRAX)Leads 3 of 6 categories
Loading custom metrics...

TTRX vs PRAX: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Is TTRX or PRAX a better buy right now?

Analysts rate Turn Therapeutics Inc.

(TTRX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — TTRX or PRAX?

Over the past 5 years, Praxis Precision Medicines, Inc.

(PRAX) delivered a total return of -20. 8%, compared to -45. 8% for Turn Therapeutics Inc. (TTRX). Over 10 years, the gap is even starker: PRAX returned -20. 9% versus TTRX's -45. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — TTRX or PRAX?

By beta (market sensitivity over 5 years), Praxis Precision Medicines, Inc.

(PRAX) is the lower-risk stock at 1. 40β versus Turn Therapeutics Inc. 's 1. 45β — meaning TTRX is approximately 4% more volatile than PRAX relative to the S&P 500.

04

Which has better profit margins — TTRX or PRAX?

Turn Therapeutics Inc.

(TTRX) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: TTRX leads at 0. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — TTRX leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — TTRX or PRAX?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is TTRX or PRAX better for a retirement portfolio?

For long-horizon retirement investors, Praxis Precision Medicines, Inc.

(PRAX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (PRAX: -20. 9%, TTRX: -45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between TTRX and PRAX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

TTRX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

PRAX

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.